Ganeshsingh Thakur

List of Publications by Year
in descending order

58	1,779	236925 25	289244 40
papers	citations	h-index	g-index

59	59	59	1563
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The endocannabinoid system impacts seizures in a mouse model of Dravet syndrome. Neuropharmacology, 2022, 205, 108897.	4.1	9
2	The type 1 cannabinoid receptor positive allosteric modulators GAT591 and GAT593 reduce spike-and-wave discharges in Genetic Absence Epilepsy Rats from Strasbourg. IBRO Neuroscience Reports, 2022, 12, 121-130.	1.6	5
3	Novel Functionalized Cannabinoid Receptor Probes: Development of Exceptionally Potent Agonists. Journal of Medicinal Chemistry, 2021, 64, 3870-3884.	6.4	8
4	Discovery of a Biased Allosteric Modulator for Cannabinoid 1 Receptor: Preclinical Anti-Glaucoma Efficacy. Journal of Medicinal Chemistry, 2021, 64, 8104-8126.	6.4	18
5	Positive allosteric modulation of type 1 cannabinoid receptors reduces spike-and-wave discharges in Genetic Absence Epilepsy Rats from Strasbourg. Neuropharmacology, 2021, 190, 108553.	4.1	22
6	Effects of the cannabinoid receptor 1 positive allosteric modulator GAT211 and acute MK-801 on visual attention and impulsivity in rats assessed using the five-choice serial reaction time task. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 109, 110235.	4.8	7
7	Stable desensitization of Î±7 nicotinic acetylcholine receptors by NS6740 requires interaction with S36 in the orthosteric agonist binding site. European Journal of Pharmacology, 2021, 905, 174179.	3.5	4
8	Design, synthesis, and pharmacological profiling of cannabinoid 1 receptor allosteric modulators: Preclinical efficacy of C2-group GAT211 congeners for reducing intraocular pressure. Bioorganic and Medicinal Chemistry, 2021, 50, 116421.	3.0	4
9	Antipsychotic potential of the type 1 cannabinoid receptor positive allosteric modulator GAT211: preclinical in vitro and in vivo studies. Psychopharmacology, 2021, 238, 1087-1098.	3.1	6
10	A benzopyran with antiarrhythmic activity is an inhibitor of Kir3.1-containing potassium channels. Journal of Biological Chemistry, 2021, 296, 100535.	3.4	7
11	Application of Fluorine- and Nitrogen-Walk Approaches: Defining the Structural and Functional Diversity of 2-Phenylindole Class of Cannabinoid 1 Receptor Positive Allosteric Modulators. Journal of Medicinal Chemistry, 2020, 63, 542-568.	6.4	40
12	Allosterically Potentiated Î±7 Nicotinic Acetylcholine Receptors: Reduced Calcium Permeability and Current-Independent Control of Intracellular Calcium. Molecular Pharmacology, 2020, 98, 695-709.	2.3	10
13	Differing Activity Profiles of the Stereoisomers of 2,3,5,6TMP-TQS, a Putative Silent Allosteric Modulator of Î±7 nAChR. Molecular Pharmacology, 2020, 98, 292-302.	2.3	12
14	Allosteric Cannabinoid Receptor 1 (CB1) Ligands Reduce Ocular Pain and Inflammation. Molecules, 2020, 25, 417.	3.8	26
15	The small molecule GAT1508 activates brain-specific GIRK1/2 channel heteromers and facilitates conditioned fear extinction in rodents. Journal of Biological Chemistry, 2020, 295, 3614-3634.	3.4	20
16	Positive Allosteric Modulation of CB1 Cannabinoid Receptor Signaling Enhances Morphine Antinociception and Attenuates Morphine Tolerance Without Enhancing Morphine- Induced Dependence or Reward. Frontiers in Molecular Neuroscience, 2020, 13, 54.	2.9	42
17	Focused structure-activity relationship profiling around the 2-phenylindole scaffold of a cannabinoid type-1 receptor agonist-positive allosteric modulator: site-III aromatic-ring congeners with enhanced activity and solubility. Bioorganic and Medicinal Chemistry, 2020, 28, 115727.	3.0	5
18	Identification of CB1 Receptor Allosteric Sites Using Force-Biased MMC Simulated Annealing and Validation by Structureâ€“Activity Relationship Studies. ACS Medicinal Chemistry Letters, 2019, 10, 1216-1221.	2.8	25

#	Article	IF	Citations
19	Heteromeric Neuronal Nicotinic Acetylcholine Receptors with Mutant Î² Subunits Acquire Sensitivity to Î±7-Selective Positive Allosteric Modulators. Journal of Pharmacology and Experimental Therapeutics, 2019, 370, 252-268.	2.5	10
20	Indomethacin Enhances Type 1 Cannabinoid Receptor Signaling. Frontiers in Molecular Neuroscience, 2019, 12, 257.	2.9	12
21	Allosteric Agonism of Î±7 Nicotinic Acetylcholine Receptors: Receptor Modulation Outside the Orthosteric Site. Molecular Pharmacology, 2019, 95, 606-614.	2.3	24
22	Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington's disease in the R6/2 mouse model. Neuropharmacology, 2019, 151, 1-12.	4.1	39
23	Macroscopic and Microscopic Activation of Î±7 Nicotinic Acetylcholine Receptors by the Structurally Unrelated Allosteric Agonist-Positive Allosteric Modulators (ago-PAMs) B-973B and GAT107. Molecular Pharmacology, 2019, 95, 43-61.	2.3	21
24	Hydrogen sulfide inhibits Kir2 and Kir3 channels by decreasing sensitivity to the phospholipid phosphatidylinositol 4,5-bisphosphate (PIP2). Journal of Biological Chemistry, 2018, 293, 3546-3561.	3.4	15
25	Enantiomer-specific positive allosteric modulation of CB1 signaling in autaptic hippocampal neurons. Pharmacological Research, 2018, 129, 475-481.	7.1	23
26	Persistent activation of Î±7 nicotinic ACh receptors associated with stable induction of different desensitized states. British Journal of Pharmacology, 2018, 175, 1838-1854.	5.4	31
27	Positive Allosteric Modulation of Cannabinoid Receptor Type 1 Suppresses Pathological Pain Without Producing Tolerance or Dependence. Biological Psychiatry, 2018, 84, 722-733.	1.3	101
28	B-973, a Novel Î±7 nAChR Ago-PAM: Racemic and Asymmetric Synthesis, Electrophysiological Studies, and in Vivo Evaluation. ACS Medicinal Chemistry Letters, 2018, 9, 1144-1148.	2.8	14
29	Enantiospecific Allosteric Modulation of Cannabinoid 1 Receptor. ACS Chemical Neuroscience, 2017, 8, 1188-1203.	3.5	78
30	Human Cannabinoid Receptor 2 Ligand-Interaction Motif: Transmembrane Helix 2 Cysteine, C2.59(89), as Determinant of Classical Cannabinoid Agonist Activity and Binding Pose. ACS Chemical Neuroscience, 2017, 8, 1338-1347.	3.5	6
31	Microwaveâ€accelerated Conjugate Addition of 2â€Arylindoles to Substituted Î²â€Nitrostyrenes in the Presence of Ammonium Trifluoroacetate: An Efficient Approach for the Synthesis of a Novel Class of CB1 Cannabinoid Receptor Allosteric Modulators. Journal of Heterocyclic Chemistry, 2017, 54, 2079-2084.	2.6	13
32	The interaction between alpha 7 nicotinic acetylcholine receptor and nuclear peroxisome proliferator-activated receptor-Î± represents a new antinociceptive signaling pathway in mice. Experimental Neurology, 2017, 295, 194-201.	4.1	23
33	Scalable, One-Pot, Microwave-Accelerated Tandem Synthesis of Unsymmetrical Urea Derivatives. Journal of Organic Chemistry, 2017, 82, 992-999.	3.2	44
34	TheIn VivoEffects of the CB₁-Positive Allosteric Modulator GAT229 on Intraocular Pressure in Ocular Normotensive and Hypertensive Mice. Journal of Ocular Pharmacology and Therapeutics, 2017, 33, 582-590.	1.4	21
35	Design and Synthesis of Cannabinoid 1 Receptor (CB1R) Allosteric Modulators: Drug Discovery Applications. Methods in Enzymology, 2017, 593, 281-315.	1.0	12
36	The Î±7 nicotinic receptor dual allosteric agonist and positive allosteric modulator GAT107 reverses nociception in mouse models of inflammatory and neuropathic pain. British Journal of Pharmacology, 2016, 173, 2506-2520.	5.4	64

#	Article	IF	Citations
37	Mapping Cannabinoid 1 Receptor Allosteric Site(s): Critical Molecular Determinant and Signaling Profile of GAT100, a Novel, Potent, and Irreversibly Binding Probe. ACS Chemical Neuroscience, 2016, 7, 776-798.	3.5	30
38	Critical Molecular Determinants of Î±7 Nicotinic Acetylcholine Receptor Allosteric Activation. Journal of Biological Chemistry, 2016, 291, 5049-5067.	3.4	43
39	Tolerance to the Diuretic Effects of Cannabinoids and Cross-Tolerance to a Â-Opioid Agonist in THC-Treated Mice. Journal of Pharmacology and Experimental Therapeutics, 2016, 358, 334-341.	2.5	7
40	Leveraging allostery to improve G protein-coupled receptor (GPCR)-directed therapeutics: cannabinoid receptor 1 as discovery target. Expert Opinion on Drug Discovery, 2016, 11, 1223-1237.	5.0	17
41	A high efficacy cannabinergic ligand (AM4054) used as a discriminative stimulus: Generalization to other adamantyl analogs and Î” 9 -THC in rats. Pharmacology Biochemistry and Behavior, 2016, 148, 46-52.	2.9	3
42	Novel Electrophilic and Photoaffinity Covalent Probes for Mapping the Cannabinoid 1 Receptor Allosteric Site(s). Journal of Medicinal Chemistry, 2016, 59, 44-60.	6.4	49
43	Probing the Carboxyester Side Chain in Controlled Deactivation (â^')-Î”⁸-Tetrahydrocannabinols. Journal of Medicinal Chemistry, 2015, 58, 665-681.	6.4	26
44	In-vivo pharmacological evaluation of the CB1-receptor allosteric modulator Org-27569. Behavioural Pharmacology, 2014, 25, 182-185.	1.7	55
45	The Activity of GAT107, an Allosteric Activator and Positive Modulator of Î±7 Nicotinic Acetylcholine Receptors (nAChR), Is Regulated by Aromatic Amino Acids That Span the Subunit Interface. Journal of Biological Chemistry, 2014, 289, 4515-4531.	3.4	36
46	Microwave-assisted expeditious and efficient synthesis of cyclopentene ring-fused tetrahydroquinoline derivatives using three-component Povarov reaction. Tetrahedron Letters, 2013, 54, 6592-6595.	1.4	34
47	Expeditious Synthesis, Enantiomeric Resolution, and Enantiomer Functional Characterization of		

#	Article	IF	Citations
55	Cannabinoid Receptors as Therapeutic Targets. Current Pharmaceutical Design, 2006, 12, 1751-1769.	1.9	55
56	CB1 Cannabinoid Receptor Ligands. Mini-Reviews in Medicinal Chemistry, 2005, 5, 631-640.	2.4	72
57	(-)-7â€²-Isothiocyanato-11-hydroxy-1â€²,1â€²-dimethylheptylhexahydrocannabinol (AM841), a High-Affinity Electrophilic Ligand, Interacts Covalently with a Cysteine in Helix Six and Activates the CB1 Cannabinoid Receptor. Molecular Pharmacology, 2005, 68, 1623-1635.	2.3	86
58	Enantiomeric resolution of a novel chiral cannabinoid receptor ligand. Journal of Proteomics, 2002, 54, 415-422.	2.4	16